The Gut-GLP-1 Connection: The Role of Akkermansia and Other Novel Probiotic Strains in Satiety and Cravings

Akkermansia muciniphila, a key player in the gut microbiome, has emerged as a significant influencer of GLP-1, a hormone with profound implications for metabolic health. Learn from Adam Perlman, MD, MPH, and Chief Medical Officer of Pendulum Therapeutics about the latest research uncovering the impact of A.muciniphila, C.butyricum, B.infantis and other novel strains on GLP-1 signaling, satiety, cravings, and probiotic avenues for metabolic disorders.

Speaker

Adam Perlman, MD, MPH: Dr. Adam Perlman, Chief Medical Officer at Pendulum Therapeutics, formerly served as the Director of Integrative Health and Wellbeing at Mayo Clinic, Florida and Medical Director for Employee Wellbeing. Prior to that, he was Associate Vice President for Health and Wellness for the Duke University Health System, overseeing Duke Integrative Medicine and the Duke Diet Center. Dr. Perlman received his BA from Tufts University and his MD from Boston University School of Medicine, completing residencies in Internal Medicine and Preventive Medicine as well as a General Internal Medicine Research Fellowship at Boston Medical Center. He earned an MPH from the Boston University School of Public Health.